Krystal Biotech (NASDAQ:KRYS) Given “Buy” Rating at Chardan Capital

Chardan Capital reissued their buy rating on shares of Krystal Biotech (NASDAQ:KRYS) in a research note published on Wednesday morning,Benzinga reports. They currently have a $212.00 target price on the stock.

KRYS has been the topic of a number of other reports. Citigroup increased their price objective on shares of Krystal Biotech from $204.00 to $206.00 and gave the stock a “neutral” rating in a research note on Tuesday, November 5th. William Blair upgraded shares of Krystal Biotech to a “strong-buy” rating in a research report on Friday, August 30th. Stifel Nicolaus boosted their price objective on shares of Krystal Biotech from $204.00 to $220.00 and gave the company a “buy” rating in a research report on Wednesday, September 11th. Cantor Fitzgerald restated an “overweight” rating on shares of Krystal Biotech in a research note on Thursday, August 29th. Finally, HC Wainwright reiterated a “buy” rating and issued a $221.00 price target on shares of Krystal Biotech in a research note on Wednesday. One equities research analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $206.67.

Krystal Biotech Trading Up 2.5 %

Shares of KRYS opened at $164.83 on Wednesday. The stock has a market capitalization of $4.74 billion, a PE ratio of 93.12 and a beta of 0.80. The firm’s 50 day moving average is $180.18 and its 200-day moving average is $185.00. Krystal Biotech has a 12 month low of $107.50 and a 12 month high of $219.34.

Krystal Biotech (NASDAQ:KRYS) last announced its quarterly earnings data on Monday, November 4th. The company reported $0.91 earnings per share for the quarter, beating the consensus estimate of $0.84 by $0.07. The firm had revenue of $83.84 million during the quarter, compared to analysts’ expectations of $82.94 million. Krystal Biotech had a return on equity of 7.54% and a net margin of 21.68%. The company’s quarterly revenue was up 879.9% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.67) EPS. Equities research analysts predict that Krystal Biotech will post 2.97 earnings per share for the current fiscal year.

Insider Activity at Krystal Biotech

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the company’s stock in a transaction dated Friday, December 13th. The stock was sold at an average price of $164.78, for a total value of $4,119,500.00. Following the completion of the transaction, the insider now owns 1,475,882 shares of the company’s stock, valued at $243,195,835.96. This represents a 1.67 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 14.10% of the stock is currently owned by company insiders.

Institutional Trading of Krystal Biotech

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Summit Trail Advisors LLC acquired a new stake in Krystal Biotech during the 3rd quarter worth approximately $1,893,000. Swiss National Bank lifted its holdings in shares of Krystal Biotech by 8.0% during the third quarter. Swiss National Bank now owns 39,100 shares of the company’s stock worth $7,117,000 after purchasing an additional 2,900 shares during the period. Sei Investments Co. lifted its holdings in shares of Krystal Biotech by 18.9% during the second quarter. Sei Investments Co. now owns 40,115 shares of the company’s stock worth $7,367,000 after purchasing an additional 6,363 shares during the period. Shaker Investments LLC OH acquired a new stake in Krystal Biotech in the third quarter valued at $532,000. Finally, Citigroup Inc. increased its holdings in Krystal Biotech by 65.4% in the third quarter. Citigroup Inc. now owns 35,084 shares of the company’s stock valued at $6,386,000 after purchasing an additional 13,874 shares during the period. 86.29% of the stock is currently owned by institutional investors.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).